慢性肾脏病中的钙：误区与真相。引言。 - Suppr

Suppr

超能文献

Calcium in chronic kidney disease: myths and realities. Introduction.

作者信息

Langman Craig B, Cannata-Andía Jorge B

机构信息

Kidney Diseases, Children's Memorial Hospital, 2300 Children's Plaza #37, Chicago IL 60614, USA.

出版信息

Clin J Am Soc Nephrol. 2010 Jan;5 Suppl 1:S1-2. doi: 10.2215/CJN.06140809.

DOI:10.2215/CJN.06140809

PMID:20089497

Abstract

摘要

相似文献

Calcium in chronic kidney disease: myths and realities. Introduction.

Clin J Am Soc Nephrol. 2010 Jan;5 Suppl 1:S1-2. doi: 10.2215/CJN.06140809.

Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population.

Clin J Am Soc Nephrol. 2010 Jan;5 Suppl 1:S41-7. doi: 10.2215/CJN.05860809.

Oral phosphate binders in patients with kidney failure.

N Engl J Med. 2010 Apr 8;362(14):1312-24. doi: 10.1056/NEJMra0912522.

Phosphate: a stealthier killer than previously thought?

Cardiovasc Pathol. 2012 Sep-Oct;21(5):372-81. doi: 10.1016/j.carpath.2012.02.008. Epub 2012 Mar 16.

Ten-year experience with sevelamer and calcium salts as phosphate binders.

Clin J Am Soc Nephrol. 2010 Jan;5 Suppl 1:S31-40. doi: 10.2215/CJN.05880809.

The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders?

Nephrol Dial Transplant. 2011 Feb;26(2):402-7. doi: 10.1093/ndt/gfq691. Epub 2010 Nov 15.

Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.

Pharmacotherapy. 2009 May;29(5):554-61. doi: 10.1592/phco.29.5.554.

Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V).

Expert Opin Pharmacother. 2010 Nov;11(16):2739-50. doi: 10.1517/14656566.2010.526107.

[The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].

Pol Merkur Lekarski. 2009 Apr;26(154):318-21.

Calcium supplementation: lessons from the general population for chronic kidney disease and back.

Curr Opin Nephrol Hypertens. 2011 Jul;20(4):369-75. doi: 10.1097/MNH.0b013e328347486a.

引用本文的文献

Substrate- and Calcium-Dependent Differential Regulation of Mitochondrial Oxidative Phosphorylation and Energy Production in the Heart and Kidney.

Cells. 2021 Dec 31;11(1):131. doi: 10.3390/cells11010131.

Survival and analysis of predictors of mortality in patients undergoing replacement renal therapy: a 20-year cohort.

BMC Nephrol. 2020 Nov 23;21(1):502. doi: 10.1186/s12882-020-02135-7.

Association of ORAI1 Genetic Polymorphism with Serum Calcium and Phosphorus Levels in Non-dialysis Chronic Kidney Disease Patients: A Case-control Study.

Cureus. 2019 Apr 29;11(4):e4564. doi: 10.7759/cureus.4564.

Laboratory Profiles of Patients on Hemodialysis - A Retrospective One Year Study in a Rural Tertiary Care Hospital.

J Clin Diagn Res. 2015 Oct;9(10):BC12-5. doi: 10.7860/JCDR/2015/14928.6697. Epub 2015 Oct 1.

Serum vitamin D and parathyroid hormone profiles in patients with various stages of renal disease.

Australas Med J. 2015 Feb 28;8(2):33-40. doi: 10.4066/AMJ.2015.2252. eCollection 2015.

Patient education for phosphorus management in chronic kidney disease.

Patient Prefer Adherence. 2013 May 3;7:379-90. doi: 10.2147/PPA.S43486. Print 2013.

Approach to cardiovascular disease prevention in patients with chronic kidney disease.

Curr Treat Options Cardiovasc Med. 2012 Aug;14(4):391-413. doi: 10.1007/s11936-012-0189-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验